Published in Front Immunol on July 17, 2012
Gr1(int)CD11b+ myeloid-derived suppressor cells in Mycobacterium tuberculosis infection. PLoS One (2013) 1.10
Myeloid-derived suppressor cells: the dark knight or the joker in viral infections? Immunol Rev (2013) 1.05
A subpopulation that may correspond to granulocytic myeloid-derived suppressor cells reflects the clinical stage and progression of cutaneous melanoma. Int Immunol (2015) 1.04
Gr-1dimCD11b+ immature myeloid-derived suppressor cells but not neutrophils are markers of lethal tuberculosis infection in mice. J Immunol (2014) 0.94
Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome. Crit Care Med (2016) 0.86
Protumor activities of the immune response: insights in the mechanisms of immunological shift, oncotraining, and oncopromotion. J Oncol (2013) 0.84
Myeloid-derived suppressor cells in sepsis. Biomed Res Int (2014) 0.79
Evaluation of the therapeutic potential of bone marrow-derived myeloid suppressor cell (MDSC) adoptive transfer in mouse models of autoimmunity and allograft rejection. PLoS One (2014) 0.78
Minimal changes in the systemic immune response after nephrectomy of localized renal masses. Urol Oncol (2014) 0.78
Cell therapy to induce allograft tolerance: time to switch to plan B? Front Immunol (2015) 0.77
Transplantation Tolerance Induction: Cell Therapies and Their Mechanisms. Front Immunol (2016) 0.76
Mesenchymal Stem Cells and Myeloid Derived Suppressor Cells: Common Traits in Immune Regulation. J Immunol Res (2016) 0.76
Disease severity and mortality can be independently regulated in a mouse model of experimental graft versus host disease. PLoS One (2015) 0.75
Persistent Inflammation, Immunosuppression and Catabolism Syndrome. Crit Care Clin (2017) 0.75
Finasteride Enhances the Generation of Human Myeloid-Derived Suppressor Cells by Up-Regulating the COX2/PGE2 Pathway. PLoS One (2016) 0.75
Expression of C/EBPβ in myeloid progenitors during sepsis promotes immunosuppression. Mol Immunol (2017) 0.75
Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol (2005) 9.27
Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol (2008) 9.25
Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol (2001) 7.43
Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood (2008) 7.15
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res (2006) 7.02
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol (2005) 6.05
Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol (2004) 5.78
Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol (2004) 5.73
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 5.65
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood (2000) 4.78
Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res (2004) 4.74
Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res (2007) 4.69
Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol (2007) 4.65
Modulation of the antitumor immune response by complement. Nat Immunol (2008) 4.53
Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res (2001) 4.49
Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res (2007) 4.39
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology (2008) 4.23
Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity (2010) 3.88
Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol (2001) 3.81
Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res (2008) 3.57
Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol (2002) 3.56
Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood (2003) 3.47
All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res (2003) 3.45
Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol (2009) 3.27
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol (2004) 3.24
Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol (2009) 3.23
Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol (2005) 3.20
L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood (2006) 3.17
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med (2005) 3.13
Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol (2000) 3.07
Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem (2001) 3.07
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol (1998) 3.03
Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol (1999) 2.94
CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res (2006) 2.92
Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res (2009) 2.90
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89
L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol (2003) 2.81
Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood (2007) 2.65
Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem (2002) 2.62
Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci U S A (2002) 2.35
SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Dev (1999) 2.31
Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol (1998) 2.25
Glutathione regulates activation-dependent DNA synthesis in highly purified normal human T lymphocytes stimulated via the CD2 and CD3 antigens. Proc Natl Acad Sci U S A (1990) 2.22
Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol (2010) 2.20
Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood (2011) 2.05
TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J Immunol (2006) 2.05
Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest (2011) 2.01
Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res (1995) 1.96
Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol (2009) 1.96
Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol (2008) 1.95
Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res (2004) 1.85
Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death. J Immunol (1999) 1.84
Immunosuppression during acute Trypanosoma cruzi infection: involvement of Ly6G (Gr1(+))CD11b(+ )immature myeloid suppressor cells. Int Immunol (2002) 1.81
Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide. J Immunol (1996) 1.75
Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells. Stem Cells (2010) 1.75
CD80+Gr-1+ myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis. J Immunol (2002) 1.73
Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev (2002) 1.66
Natural suppressor (NS) cells, neonatal tolerance, and total lymphoid irradiation: exploring obscure relationships. Annu Rev Immunol (1984) 1.61
Transport of cystine and cysteine in mammalian cells. Biochim Biophys Acta (1984) 1.61
VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res (2001) 1.55
Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice. J Clin Invest (2010) 1.55
Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood (2011) 1.47
Extracellular redox modulation by regulatory T cells. Nat Chem Biol (2009) 1.45
Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses. J Immunol (2004) 1.42
Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med (Berl) (2003) 1.38
Molecular mechanisms and therapeutic reversal of immune suppression in cancer. Curr Cancer Drug Targets (2007) 1.37
Endotoxin-induced myeloid-derived suppressor cells inhibit alloimmune responses via heme oxygenase-1. Am J Transplant (2009) 1.35
Macrophage arginine metabolism and the inhibition or stimulation of cancer. J Immunol (1992) 1.35
Induced SHIP deficiency expands myeloid regulatory cells and abrogates graft-versus-host disease. J Immunol (2007) 1.34
Superantigen-induced CD4 T cell tolerance mediated by myeloid cells and IFN-gamma. J Immunol (2000) 1.28
Inhibition of PPARγ in myeloid-lineage cells induces systemic inflammation, immunosuppression, and tumorigenesis. Blood (2011) 1.23
Inhibition of MHC II gene transcription by nitric oxide and antioxidants. Curr Pharm Des (2004) 1.19
Human inhibitory receptor immunoglobulin-like transcript 2 amplifies CD11b+Gr1+ myeloid-derived suppressor cells that promote long-term survival of allografts. Transplantation (2008) 1.17
Type 1 T helper cells induce the accumulation of myeloid-derived suppressor cells in the inflamed Tgfb1 knockout mouse liver. Hepatology (2010) 1.12
Association of increased immunostaining for inducible nitric oxide synthase and nitrotyrosine with fibroblast growth factor transformation in pancreatic cancer. Arch Surg (1999) 1.12
Non-irradiation-derived reactive oxygen species (ROS) and cancer: therapeutic implications. Amino Acids (2006) 1.09
Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma + vaccination model. J Neuroimmunol (2010) 1.08
In vivo induction of myeloid suppressor cells and CD4(+)Foxp3(+) T regulatory cells prolongs skin allograft survival in mice. Cell Transplant (2010) 1.08
Regulatory T cells interfere with glutathione metabolism in dendritic cells and T cells. J Biol Chem (2010) 1.01
Reactive oxygen species production by blood neutrophils of patients with laryngeal carcinoma and antioxidative enzyme activity in their blood. Acta Oncol (2004) 1.00
T-cell subsets and suppressor cells in human bone marrow. Blood (1992) 0.95
Mice infected with Schistosoma mansoni develop a novel non-T-lymphocyte suppressor population which inhibits virus-specific CTL induction via a soluble factor. Microbes Infect (2001) 0.95
Spleen but not tumor infiltration by dendritic and T cells is increased by intravenous adenovirus-Flt3 ligand injection. Cancer Gene Ther (2007) 0.93
T cells from late tumor-bearing mice express normal levels of p56lck, p59fyn, ZAP-70, and CD3 zeta despite suppressed cytolytic activity. J Exp Med (1995) 0.93
Nitric oxide mediation of active immunosuppression associated with graft-versus-host reaction. Blood (1999) 0.86
Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors. Curr Opin Hematol (1999) 0.83
Natural suppressor cells. Prog Clin Biol Res (1989) 0.82
Renal transplant recipients have elevated frequencies of circulating myeloid-derived suppressor cells. Nephrol Dial Transplant (2011) 0.82
Infiltrating monocytes versus resident Kupffer cells: do alternatively activated macrophages need to be targeted alternatively? Hepatology (2011) 0.78
Costimulation blockade with belatacept in renal transplantation. N Engl J Med (2005) 4.86
Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol (2008) 1.95
One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial. Transplantation (2016) 1.68
Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int (2010) 1.57
Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol (2005) 1.36
Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol (2010) 1.31
Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle. Mol Ther (2009) 1.21
Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med (2010) 1.17
Ten-year survival of second kidney transplants: impact of immunologic factors and renal function at 12 months. Kidney Int (2003) 1.07
Reply to "Biologics in organ transplantation". Transpl Int (2012) 1.07
Tuberculosis following kidney transplantation: clinical features and outcome. A French multicentre experience in the last 20 years. Nephrol Dial Transplant (2011) 1.05
Acute graft pyelonephritis and long-term kidney allograft outcome. Kidney Int (2002) 1.01
Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation. J Cell Mol Med (2009) 1.00
Long-term IgG response to porcine Neu5Gc antigens without transmission of PERV in burn patients treated with porcine skin xenografts. J Immunol (2013) 0.96
Rapid failure of pig islet transplantation in non human primates. Xenotransplantation (2002) 0.95
Transgenic expression of CTLA4-Ig by fetal pig neurons for xenotransplantation. Transgenic Res (2005) 0.93
Anti-CD28 antibody-induced kidney allograft tolerance related to tryptophan degradation and TCR class II B7 regulatory cells. Am J Transplant (2005) 0.93
Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients. J Immunol (2007) 0.92
Control of transplant tolerance and intragraft regulatory T cell localization by myeloid-derived suppressor cells and CCL5. J Immunol (2012) 0.92
A more selective costimulatory blockade of the CD28-B7 pathway. Transpl Int (2010) 0.89
Characterization of human CD55 and CD59 transgenic pigs and kidney xenotransplantation in the pig-to-baboon combination. Transplantation (2004) 0.88
Successful endovascular treatment of bilateral renal artery paradoxical embolus by a modified standard technique. Nephrol Dial Transplant (2006) 0.86
TNF blockade abrogates the induction of T cell-dependent humoral responses in an allotransplantation model. J Leukoc Biol (2011) 0.85
Alternatives to calcineurin inhibition in renal transplantation: belatacept, the first co-stimulation blocker. Immunotherapy (2010) 0.85
Expression of heme oxygenase-1 in neural stem/progenitor cells as a potential mechanism to evade host immune response. Stem Cells (2012) 0.84
Depletion of LAG-3 positive cells in cardiac allograft reveals their role in rejection and tolerance. Transplantation (2007) 0.84
Myeloid-derived suppressor cells in transplantation. Curr Opin Organ Transplant (2010) 0.83
Kidney and liver transplantation in patients with autosomal recessive polycystic kidney disease: a multicentric study. Nephrol Dial Transplant (2011) 0.82
Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function. Transpl Int (2007) 0.82
Depleting T-cell subpopulations in organ transplantation. Transpl Int (2008) 0.82
Antagonist properties of monoclonal antibodies targeting human CD28: role of valency and the heavy-chain constant domain. MAbs (2012) 0.81
Risk in drug trials. Lancet (2006) 0.81
IL-7 receptor blockade following T cell depletion promotes long-term allograft survival. J Clin Invest (2014) 0.81
Dextran sulfate acts as an endothelial cell protectant and inhibits human complement and natural killer cell-mediated cytotoxicity against porcine cells. Transplantation (2003) 0.81
An in vitro evaluation of the potential suitability of peripheral blood CD14(+) and bone marrow CD34(+)-derived dendritic cells for a tolerance inducing regimen in the primate. J Immunol Methods (2005) 0.80
Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events. Transplantation (2005) 0.80
[Renal transplantation after excision of an angiomyolipoma on living donor kidney]. Prog Urol (2004) 0.80
Transplant tolerance is associated with reduced expression of cystathionine-γ-lyase that controls IL-12 production by dendritic cells and TH-1 immune responses. Blood (2012) 0.79
Trophic and immunoregulatory properties of neural precursor cells: benefit for intracerebral transplantation. Exp Neurol (2010) 0.79
Dominant tolerance to kidney allografts induced by anti-donor MHC class II antibodies: cooperation between T and non-T CD103+ cells. J Immunol (2006) 0.79
Specific humoral rejection of a pancreas allograft in a recipient of pancreas after kidney transplantation. Nephrol Dial Transplant (2007) 0.79
Interleukin 7 receptor alpha as a potential therapeutic target in transplantation. Arch Immunol Ther Exp (Warsz) (2009) 0.79
Prognostic significance of graft Foxp3 expression in renal transplant recipients: a critical review and attempt to reconcile discrepancies. Nephrol Dial Transplant (2012) 0.78
hCTLA4-Ig transgene expression in keratocytes modulates rejection of corneal xenografts in a pig to non-human primate anterior lamellar keratoplasty model. Xenotransplantation (2014) 0.78
The study of mitoxantrone as a potential immunosuppressor in transgenic pig renal xenotransplantation in baboons: comparison with cyclophosphamide. Xenotransplantation (2004) 0.78
Evaluation of the efficacy and safety of a slow conversion from calcineurin inhibitor- to sirolimus-based therapies in maintenance renal-transplant patients presenting with moderate renal insufficiency. Transpl Int (2007) 0.78
Endothelial cell protection by dextran sulfate: a novel strategy to prevent acute vascular rejection in xenotransplantation. Am J Transplant (2004) 0.78
Induction of regulatory cells and control of cellular but not vascular rejection by costimulation blockade in hamster-to-rat heart xenotransplantation. Xenotransplantation (2007) 0.78
Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses. Blood (2002) 0.78
Current cellular immunological hurdles in pig-to-primate xenotransplantation. Transpl Immunol (2008) 0.78
Association of rapamycin and co-stimulation blockade using anti-B7 antibodies in renal allotransplantation in baboons. Nephrol Dial Transplant (2004) 0.77
Gene transfer of human CD40Ig does not prevent rejection in a non-human primate kidney allotransplantation model. Transpl Immunol (2012) 0.77
Local control of the host immune response performed with mesenchymal stem cells: perspectives for functional intracerebral xenotransplantation. J Cell Mol Med (2014) 0.77
Cellular participation in delayed xenograft rejection of hCD55 transgenic pig hearts by baboons. Xenotransplantation (2003) 0.76
Steroid avoidance versus steroid withdrawal after simultaneous pancreas-kidney transplantation. Am J Transplant (2005) 0.76
The effect of immunoglobulin immunadsorptions on delayed xenograft rejection of human CD55 transgenic pig kidneys in baboons. Xenotransplantation (2003) 0.76
Acute humoral rejection of renal transplants in alloimmunized pigs. J Surg Res (2007) 0.76
Preclinical testing of anti-human CD28 Fab' antibody in a novel nonhuman primate (NHP) small animal rodent model of xenogenic graft-versus-host disease (GVHD). Transplantation (2016) 0.75
Antibodies directed against AB blood antigens or human leukocyte antigen molecules activate different intracellular pathways explaining their differential effects toward accommodation. Transplantation (2012) 0.75
Correction: Selective Blockade of CD28-Mediated T Cell Costimulation Protects Rhesus Monkeys against Acute Fatal Experimental Autoimmune Encephalomyelitis. J Immunol (2015) 0.75
Six months anti-viral prophylaxis significantly decreased cytomegalovirus disease compared with no anti-viral prophylaxis following renal transplantation. Transpl Int (2010) 0.75
Early and irreversible recurrence MPO-ANCA-positive glomerulonephritis after renal transplantation. Clin Nephrol (2015) 0.75
Autoimmune responses against renal tissue proteins in long-term surviving allograft recipients. Transpl Int (2009) 0.75
Clinical, Genetic and Innate Immunity Characteristics of Melanoma in Organ Transplant Recipients. Acta Derm Venereol (2016) 0.75
Editorial xenotransplantation. Curr Opin Organ Transplant (2009) 0.75
Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine. Transpl Int (2007) 0.75
The effect of mitoxantrone on anti-pig immunization in baboons. Xenotransplantation (2003) 0.75
[On the acceptability of xenografts]. Med Sci (Paris) (2005) 0.75